Fairvalue-Calculator Fairvalue-Calculator
EN DE

InBody Co (041830) Fair Value & Analysis

Healthcare · KR · Market cap 603B KRW

Price46,300 KRW
Fair Value49,984 KRW
Upside+8.0%
Quality94/100
Evidence: High Range 37,377 KRW – 62,481 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

InBody Co (041830) currently trades at 46,300 KRW, while our model-based Fair Value estimate is 49,984 KRW — implying the stock looks roughly 8.0% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

i-SENS, Inc (099190) +7% Value Added Technology Co (043150) +238% Mediana Co (041920) +6% Meta Biomed Co (059210) +176% Sewoon Medical Co (100700) +180% Medicon Hellas S.A (MEDIC) -35%

Frequently asked questions

Is InBody Co (041830) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 49,984 KRW versus a price of 46,300 KRW — about +8% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 041830?
Our 21-model fair value for InBody Co is 49,984 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 46,300 KRW.
What is the quality score of 041830?
InBody Co has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.